These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28432106)

  • 21. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
    Chang PL; Lindheim SR; Lowre C; Ferin M; Gonzalez F; Berglund L; Carmina E; Sauer MV; Lobo RA
    J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obesity and the polycystic ovary syndrome.
    Gambineri A; Pelusi C; Vicennati V; Pagotto U; Pasquali R
    Int J Obes Relat Metab Disord; 2002 Jul; 26(7):883-96. PubMed ID: 12080440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Basic research in PCOS: are we reaching new frontiers?
    Ben-Shlomo I; Younis JS
    Reprod Biomed Online; 2014 Jun; 28(6):669-83. PubMed ID: 24768413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiopoietins/TIE2 system and VEGF are involved in ovarian function in a DHEA rat model of polycystic ovary syndrome.
    Abramovich D; Irusta G; Bas D; Cataldi NI; Parborell F; Tesone M
    Endocrinology; 2012 Jul; 153(7):3446-56. PubMed ID: 22577112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prohibitin-induced, obesity-associated insulin resistance and accompanying low-grade inflammation causes NASH and HCC.
    Ande SR; Nguyen KH; Grégoire Nyomba BL; Mishra S
    Sci Rep; 2016 Mar; 6():23608. PubMed ID: 27005704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polycystic ovary syndrome, obesity and reproductive implications.
    Hirschberg AL
    Womens Health (Lond); 2009 Sep; 5(5):529-40; quiz 541-2. PubMed ID: 19702452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polycystic ovary syndrome and female reproduction.
    Elghblawi E
    Br J Nurs; 2007 Oct 11-24; 16(18):1118-21. PubMed ID: 18073681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The New Zealand obese mouse model of obesity insulin resistance and poor breeding performance: evaluation of ovarian structure and function.
    Radavelli-Bagatini S; Blair AR; Proietto J; Spritzer PM; Andrikopoulos S
    J Endocrinol; 2011 Jun; 209(3):307-15. PubMed ID: 21429962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polycystic ovary syndrome in the Indian Subcontinent.
    Allahbadia GN; Merchant R
    Semin Reprod Med; 2008 Jan; 26(1):22-34. PubMed ID: 18181079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.
    Westerveld HE; Hoogendoorn M; de Jong AW; Goverde AJ; Fauser BC; Dallinga-Thie GM
    Pharmacol Ther; 2008 Sep; 119(3):223-41. PubMed ID: 18602948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors.
    Broekmans FJ; Knauff EA; Valkenburg O; Laven JS; Eijkemans MJ; Fauser BC
    BJOG; 2006 Oct; 113(10):1210-7. PubMed ID: 16972863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.
    Thierry van Dessel HJ; Lee PD; Faessen G; Fauser BC; Giudice LC
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3030-5. PubMed ID: 10487660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polycystic ovaries and obesity.
    Messinis IE; Messini CI; Anifandis G; Dafopoulos K
    Best Pract Res Clin Obstet Gynaecol; 2015 May; 29(4):479-88. PubMed ID: 25487256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role of leptin in polycystic ovary syndrome].
    Marciniak A; Starczewski A
    Pol Merkur Lekarski; 2008 Oct; 25(148):390-3. PubMed ID: 19145943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle.
    Lockwood GM; Muttukrishna S; Groome NP; Matthews DR; Ledger WL
    J Clin Endocrinol Metab; 1998 May; 83(5):1730-5. PubMed ID: 9589683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leptin concentrations in the polycystic ovary syndrome.
    Mantzoros CS; Dunaif A; Flier JS
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1687-91. PubMed ID: 9177364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature.
    Azziz R
    J Clin Endocrinol Metab; 2006 Mar; 91(3):781-5. PubMed ID: 16418211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The frequency of insulin resistance calculated upon the basis of a fasting glucose to insulin ratio and characteristics of insulin resistant women with polycystic ovary syndrome.
    Popovska-Dimova Z; Krstevska B
    Prilozi; 2006 Jul; 27(1):87-95. PubMed ID: 16985482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.